f Whether isavuconazole, an extended-spectrum triazole, possesses synergistic activity in combination therapy with echinocandins or amphotericin B for the treatment of invasive molds infections has not been studied. Our in vitro combination studies showed that isavuconazole and micafungin are synergistically active against Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Cunninghamella bertholletiae. These results suggest that isavuconazole, in combination with micafungin, may have a role in the treatment of invasive aspergillosis and warrants further investigation.
I
nvasive mold infections are important causes of morbidity and mortality in immunocompromised hosts. Response to treatment with a single antifungal agent is often inadequate, as acquired resistance and breakthrough infections have been reported among patients with long-term exposure to even the newest of antifungal agents (1) (2) (3) . Combination antifungal therapy provides a potential strategy to improve antimicrobial activity and clinical outcomes (4, 5) . Isavuconazole is an extended-spectrum antifungal triazole with favorable pharmacokinetic and safety profiles and in vitro activity against a wide variety of fungal pathogens, including non-Aspergillus spp., Fusarium spp., Scedosporium spp., and Mucorales (6, 7) . Whether isavuconazole possesses synergistic activity when combined with echinocandins or polyenes is unknown. Herein, we examine the combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important mold isolates.
A collection of 11 mold isolates was used in this study. Candida parapsilosis (ATCC 22019), Candida krusei (ATCC 6258), and Aspergillus flavus (ATCC 204304) were used for quality control. Amphotericin B deoxycholate (AMB) (Sigma-Aldrich, St. Louis, MO), micafungin (MFG) (Astellas Pharma US, Inc., Northbrook, IL), and isavuconazole (ISA) (Basilea Pharmaceutica, Basel, Switzerland) were used in this study. The antifungal agents were obtained in lyophilized powder form and were prepared and preserved according to the manufacturer's instructions. Inoculum preparation and MICs were determined according to the Clinical and Laboratory Standards Institute reference method for broth dilution antifungal susceptibility testing (CLSI M38-A2) (8) .
The in vitro combination testing between ISA and MFG or AMB was performed using a two-dimensional (8-by-12) checkerboard microdilution method in sterile 96-well flat-bottom microtitration plates. The choice of the appropriate range of drug concentrations was based on the MIC findings on each individual drug and isolate. ISA and MFG or AMB were added in plate wells as has been described elsewhere (9, 10) .
The combined effects of the antifungal agents were quantified after incubation for 48 h by using the metabolic reduction assay XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-tetrazolim-5-carboxanilide) and 25 M menadione as the final electron acceptor agent, as described previously (11) . Interactions between the antifungal agents were analyzed with the Loewe additivity model (12) using the fractional inhibitory concentration (FIC) index and the Bliss independence model (9, (13) (14) (15) (16) (17) .
The results of the FIC index model are summarized in Table 1 . For the ISA-MFG combinations, the median FIC indices of all the strains ranged from 0.28 to 1.06. These indices for A. fumigatus, A. flavus, Aspergillus terreus, Cunninghamella bertholletiae, Lichtheimia corymbifera, and Scedosporium apiospermum indicate synergy. In addition, a mean FIC value of Ͼ1.25 for all replicates was not noted in any of the mold isolates tested, indicating that no antagonism was found. For the ISA-AMB combinations, the median FIC indices of all strains, with the exception of those for A. fumigatus, A. flavus, and Fusarium oxysporum, ranged from 1 to 1.18, indicating an additive effect. However, a mean FIC value of Ͻ1, indicating synergism, was not noted in any of the isolates tested.
The results of Bliss independence drug interaction analysis for the in vitro interactions of ISA-MFG and ISA-AMB are summarized in Table 2 . The ISA-MFG combination resulted in a synergistic interaction in A. fumigatus, A. flavus, A. terreus, and C. bertholletiae. The degree of synergy was the highest among the Aspergillus species, ranging from 29.98% to 65.59%. Only for F. oxysporum was the ISA-MFG interaction antagonistic, while for Mucor circinelloides, Rhizopus microsporus, and Rhizopus oryzae, the combined ISA-MFG effect resulted in an indifferent interaction. For Fusarium solani, L. corymbifera, and S. apiospermum, the type of interaction was drug concentration dependent.
The ISA-AMB combination resulted in antagonistic interactions in A. fumigatus, A. flavus, F. solani, and R. microsporus, while for S. apiospermum, the interaction was synergistic. For L. corymbifera, M. circinelloides, and R. oryzae, the ISA-AMB combination resulted in indifferent interactions. The type of ISA-AMB interaction against A. terreus, F. oxysporum, and C. bertholletiae appeared to be concentration dependent.
Overall, our results show that the ISA-MFG combination has consistent synergistic effects against A. terreus, A. fumigatus, A. flavus, and C. bertholletiae. In addition, the ISA-AMB combination has low-grade antagonistic effects against A. fumigatus, A. flavus, F. solani, and R. microsporus. Moreover, the ISA-MFG combination was found to be concentration and organism dependent (i.e., for C. bertholletiae and L. corymbifera at ISA concentrations near the MIC, the interactions were synergistic, and at low ISA concentrations, the interactions were antagonistic). By comparison, for S. apiospermum, synergistic ISA-MFG interactions were noted at low ISA concentrations and antagonistic interactions at high ISA concentrations. From the mechanistic and clinical perspectives, the former findings about S. apiospermum ISA-MFG interactions seem intriguing. However, the low magnitude of Bliss antagonism between ISA and MFG, which was beyond the sensitivity of the XTT assay to detect fungal growth and may also be due to the variation of background absorbance (18) , makes this interaction not clinically considerable. From a clinical perspective, the range of in vitro ISA concentrations at which the synergistic interactions were observed fell within achievable plasma concen- The type of ISA-AMB synergy was drug concentration dependent for A. terreus, F. oxysporum, and C. bertholletiae; that is, treatment of A. terreus showed antagonistic interactions at high AMB (1 to 8 mg/liter) and ISA (1 to 16 mg/liter) concentrations, while at low AMB (0.125 to 0.5 mg/liter) and ISA (0.250 to 2 mg/liter) concentrations, the interactions were synergistic. For F. oxysporum, synergistic interactions were noted with a low concentration of ISA (0.0625 mg/liter) and with a range of AMB concentrations (from 0.5 to 4 mg/liter). On the contrary, the combination of high concentrations of ISA (8 to 32 mg/liter) and AMB at a range (from 0.125 to 8 mg/liter) resulted in antagonistic interactions. For C. bertholletiae, low-level synergistic interactions were noted at low concentrations of AMB (0.125 to 0.5 mg/liter) and at high concentrations of ISA (4 to 32 mg/liter), while at higher concentrations of AMB (1 to 8 mg/liter) and ISA (from 2 to 32 mg/liter), the interactions were antagonistic. trations of healthy volunteers (19) . However, the antagonistic interactions occurred at concentrations that exceeded safely achievable levels. Furthermore, the degree of the ISA-MFG antagonistic interactions was low enough (mean %⌬E value, Ϫ0.61%) ( Table  2) as to be clinically negligible.
Drug-drug interactions between antifungal agents may not necessarily be the same at all concentrations. The power of Bliss surface analysis reveals that, at certain concentrations, synergy may be present, while at other concentrations, antagonism may occur. For a given species, clinicians may assess these concentration-dependent interactions by assessing the predominant direction of percent synergy or percent antagonism. For example, for S. apiospermum, the predominant interaction is synergy (⌬E ϭ 8.95% [range, 5.22% to 16.46%]), while antagonism is only minimally detectable (⌬E ϭ Ϫ0.61% [range, Ϫ0.21% to Ϫ1.7%]). Yet, depending on the relative concentrations of the antifungal agents, synergy or antagonism may be observed at different time points over the dosing interval. Within a given tissue site, these dynamic changes of synergy and antagonism may occur. The final in vivo outcome will be determined by the predominant drug interaction of synergy (ϩ⌬E), indifference (⌬E ϭ 0), or antagonism (Ϫ⌬E).
The correlation of in vitro-in vivo results has long been an issue of controversy. Our combination studies of invasive aspergillosis in a persistently neutropenic rabbit model have been correlated with in vitro combination studies (20) (21) (22) (23) . The key to correlation between in vitro and in vivo outcomes of invasive aspergillosis is the presence of circulating neutrophils. Specifically, while neutrophils contribute to the antifungal effect in vivo, they are absent in in vitro combination studies. As murine models of aspergillosis may be transiently neutropenic, their correlation with in vitro combination studies may be poor.
In conclusion, the in vitro findings of the present study collectively indicate that the isavuconazole-micafungin combination is synergistic for A. fumigatus, A. flavus, A. terreus, and one of the most virulent Mucorales species, C. bertholletiae. This in vitro synergism may prove effective for the treatment of difficult-to-treat Aspergillus infections. Animal model and clinical studies are warranted to further elucidate the potential of the isavuconazoleechinocandin combination for difficult-to-treat filamentous fungal infections.
